此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PLN-101095 在成人晚期或转移性实体瘤中的 1 期研究

2026年11月6日 更新者:Pliant Therapeutics, Inc.

一项 1a/1b 期多中心、开放标签剂量递增/扩展研究,旨在评估 PLN-101095 单药治疗以及与 Pembrolizumab 联合治疗晚期或转移性实体瘤成人受试者的安全性、耐受性、药代动力学和抗肿瘤活性的初步证据服用派姆单抗期间疾病进展的人

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.

The study will consist of 2 main parts:

  • Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
  • Part 2: Dose-expansion cohorts using Simon's 2-stage design

研究概览

研究类型

介入性

注册 (估计的)

124

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Pliant Therapeutics Medical Monitor
  • 电话号码:clintrials@pliantrx.com
  • 邮箱:clintrials@pliantrx.com

学习地点

    • Connecticut
      • New Haven、Connecticut、美国、06511
        • 完全的
        • Yale University
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20007
        • 招聘中
        • Georgetown University Medical Center
        • 接触:
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Winship Cancer Institute of Emory University
        • 接触:
    • Michigan
      • Grand Rapids、Michigan、美国、49546
        • 招聘中
        • South Texas Accelerated Research Therapeutics (START)
        • 接触:
    • Missouri
      • St Louis、Missouri、美国、63110
        • 招聘中
        • Washington University Medicine
        • 接触:
    • New Jersey
      • East Brunswick、New Jersey、美国、08816
      • New Brunswick、New Jersey、美国、08901
        • 招聘中
        • Rutgers Cancer Institute of New Jersey
        • 接触:
    • New York
      • Lake Success、New York、美国、11042
        • 招聘中
        • START New York Long Island LLC
        • 接触:
    • North Carolina
      • Wilson、North Carolina、美国、27893
        • 招聘中
        • Carolina Cancer Research Center
        • 接触:
    • South Dakota
      • Sioux Falls、South Dakota、美国、57105
    • Tennessee
      • Nashville、Tennessee、美国、37203
    • Texas
      • Austin、Texas、美国、78758
      • Fort Worth、Texas、美国、76104
        • 招聘中
        • START Center for Clinical Research
        • 接触:
      • Houston、Texas、美国、77030
        • 招聘中
        • University of Texas MD Anderson Cancer Center
        • 接触:
      • Houston、Texas、美国、77054
      • San Antonio、Texas、美国、78229
        • 招聘中
        • UT Health San Antonio's Mays Cancer Center
        • 接触:
    • Utah
      • West Valley City、Utah、美国、84119
    • Virginia
      • Fairfax、Virginia、美国、22031
        • 招聘中
        • Inova Schar Cancer Institute
        • 接触:
      • Fairfax、Virginia、美国、22031
    • Washington
      • Edmonds、Washington、美国、98026
        • 招聘中
        • Swedish Cancer Institute Medical Oncology
        • 接触:
    • Barcelona
      • Barcelona、Barcelona、西班牙、08023
        • 招聘中
        • Hospital Universitari Quirónsalud (NEXT Barcelona)
        • 接触:
      • Barcelona、Barcelona、西班牙、08023
        • 招聘中
        • START Barcelona - Hospital HM Nou Delfos
        • 接触:
      • Barcelona、Barcelona、西班牙、08035
        • 招聘中
        • Hospital Universitari Vall d'Hebron - VHIO
        • 接触:
    • La Rioja
      • Logroño、La Rioja、西班牙、26006
        • 招聘中
        • START Center for Cancer Research - La Rioja
        • 接触:
    • Madrid
      • Madrid、Madrid、西班牙、28040
        • 招聘中
        • START Madrid - Hospital Universitario Fundación Jiménez Díaz
        • 接触:
      • Madrid、Madrid、西班牙、28050
        • 招聘中
        • START Madrid - Centro Integral Oncológico Clara Campal
        • 接触:
    • Pozuelo de Alarcón
      • Madrid、Pozuelo de Alarcón、西班牙、28223
        • 招聘中
        • University Hospital Quironsalud Madrid (NEXT Madrid)
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Has histologically or cytologically confirmed advanced or metastatic solid tumor
  2. Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
  3. Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
  4. Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
  5. At least 1 measurable lesion, as defined by RECIST v1.1
  6. Estimated survival of ≥3 months
  7. Have adequate bone marrow and organ function.
  8. A female participant is eligible to participate if she is not pregnant, not breastfeeding

Exclusion Criteria:

  1. Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
  2. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
  3. Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
  4. Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
  5. Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
  6. Has an active autoimmune disease that has required systemic treatment in the past 2 years
  7. Has known active CNS metastases (brain and/or leptomeningeal metastases)
  8. Has significant cardiac disease
  9. Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
  10. Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1 Dose Escalation - 250 mg BID

Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

实验性的:Part 1 Dose Escalation - 500 mg BID

PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

实验性的:Part 1 Dose Escalation - 1000 mg BID

PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

实验性的:Part 1 Dose Escalation - 1000 mg TID

PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

实验性的:Part 1 Dose Escalation - 2000 mg BID

PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

实验性的:Part 2 Dose Expansion - NSCLC

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC)

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

实验性的:Part 2 Dose Expansion - ccRCC

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC)

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

实验性的:Part 2 Dose Expansion - TMB-high solid tumors

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
大体时间:First dose to 35 days

Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications.

First dose to 35 days
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
大体时间:Day 1 until 16 weeks after end of study treatment regimen

Proportion of participants with treatment-emergent adverse events and serious adverse events.

Day 1 until 16 weeks after end of study treatment regimen
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
大体时间:First dose to disease progression or death from any cause, whichever occurs first.

Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1.

First dose to disease progression or death from any cause, whichever occurs first.
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
大体时间:First dose to disease progression or death from any cause, whichever occurs first.

Proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1.

First dose to disease progression or death from any cause, whichever occurs first.

次要结果测量

结果测量
措施说明
大体时间
PK of PLN-101095 monotherapy in Parts 1 and 2
大体时间:Day 14, 0 to up to 12 hours

Maximum drug concentration (Cmax)

Day 14, 0 to up to 12 hours
PK of PLN-101095 monotherapy in Parts 1 and 2
大体时间:Day 14, 0 to up to 12 hours

Time to Cmax (Tmax)

Day 14, 0 to up to 12 hours
PK of PLN-101095 monotherapy in Parts 1 and 2
大体时间:Day 14, 0 to up to 12 hours

Area under the concentration-time curve (AUC0-τ)

Day 14, 0 to up to 12 hours
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
大体时间:First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first

Duration of response (DOR) for objective responders

First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
大体时间:First dose to progression or death from any cause, whichever occurs first

Time on treatment (TOT) for objective responders

First dose to progression or death from any cause, whichever occurs first

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Pliant Therapeutics Medical Monitor、Pliant Therapeutics, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年8月30日

初级完成 (估计的)

2030年6月1日

研究完成 (估计的)

2030年6月1日

研究注册日期

首次提交

2024年1月26日

首先提交符合 QC 标准的

2024年2月13日

首次发布 (实际的)

2024年2月21日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • PLN-101095-ONC-101

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅